This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	<i>HNF1 homeobox B</i> (<i>HNF1B</i>)	<p>Patient studies suggest genetic and epigenetic variation in <i>HNF1B</i> could be useful for the classification and prognosis of ovarian cancers. In ovarian tumor samples, epigenetic DNA analysis showed that the <i>HNF1B</i> promoter region was methylated in 42% of serous tumors, whereas methylation levels were 0% in clear cell ovarian tumors. In samples from 44,308 subjects, genetic analysis showed that the rs7405776 SNP in <i>HNF1B</i> was associated with increased risk for invasive serous ovarian cancer, whereas the rs11651755 SNP in <i>HNF1B</i> was associated with decreased risk for clear cell ovarian cancer. Next steps could include developing an assay to classify ovarian cancers based on genetic and epigenetic variation in <i>HNF1B</i>.</p> <p>SciBX 6(14); doi:10.1038/scibx.2013.336 Published online April 11, 2013</p>	Patent and licensing status unavailable	<p>Shen, H. <i>et al. Nat. Commun.</i>; published online March 27, 2013; doi:10.1038/ncomms2629</p> <p>Contact: Celeste Leigh Pearce, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, Calif. e-mail: cpearce@usc.edu</p> <p>Contact: Ellen L. Goode, Mayo Clinic, Rochester, Minn. e-mail: egoode@mayo.edu</p>